Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0620
0.00 (0.00%)
Jun 16, 2026, 9:37 AM EST
Provectus Biopharmaceuticals Employees
Provectus Biopharmaceuticals had 6 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$9,580
Profits / Employee
-$930,200
Market Cap
26.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - |
| Dec 31, 2024 | 6 | 2 | 50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 2 | 100.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oncotelic Therapeutics | 43 |
| NKGen Biotech | 26 |
| Zeo ScientifiX | 20 |
| Nuo Therapeutics | 10 |
| Inhibitor Therapeutics | 8 |
| ZIVO Bioscience | 7 |
| Anebulo Pharmaceuticals | 3 |
| Galera Therapeutics | 3 |
Provectus Biopharmaceuticals News
- 8 days ago - Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders - GlobeNewsWire
- 4 weeks ago - Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End - GlobeNewsWire
- 6 weeks ago - Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee - GlobeNewsWire
- 2 months ago - Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment - GlobeNewsWire
- 8 months ago - Provectus announces publication of preclinical research on PV-10 - TheFly
- 8 months ago - Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy - GlobeNewsWire
- 9 months ago - Provectus initiates preclinical study of oral PV-10 in bladder cancer - TheFly